ARCHIVES

Kadcyla Extends Median PFS In Open-Label Phase III Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 10 | October 25, 2013

Download PDF Visit The Full Archive

Related Articles

Federal AIDS Funds Tp $2 Bil.; Term Proposed For NIH Director

October 19, 1990

In Brief: Peter Pisters named CEO of University Health Network in Toronto

August 8, 2014

NCI Chief Operating Officer Lawrence Ray To Retire

April 24, 2009

Organ Site Program Fate On Line, Gets Review Next Week

November 20, 1981

In Brief: Hatch Bill Would Require NDA Sponsors To Pay Fee; IND, Generic Drug NDAs Would Be Exempt

August 22, 1986

After Year-Long Review, Varmus Removes “Reasonable Pricing” Clause From CRADA

April 14, 1995